Trospium Chloride Dosing for Overactive Bladder
The recommended dose of trospium chloride for adults with overactive bladder is 20 mg twice daily (immediate-release) or 60 mg once daily in the morning on an empty stomach (extended-release formulation). 1
Standard Adult Dosing
Extended-Release Formulation
- Dose: 60 mg once daily in the morning
- Administration: Take with water on an empty stomach, at least one hour before a meal 1
- This formulation provides the convenience of once-daily dosing with demonstrated efficacy over 12 weeks
Immediate-Release Formulation
- Dose: 20 mg twice daily
- Administration: Should be taken on an empty stomach or at least one hour before meals (food reduces absorption by 70-80%) 2
Dose Adjustments for Special Populations
Elderly Patients (≥65 Years)
No routine dose adjustment is required for elderly patients based solely on age. 3 However, important considerations include:
- Trospium 60 mg extended-release has been specifically studied and proven efficacious and well-tolerated in patients ≥75 years of age 4
- Body surface area (BSA) is the only demographic factor that significantly impacts trospium pharmacokinetics—not age itself 3
- Key advantage in elderly: Trospium is a quaternary ammonium compound with minimal CNS penetration, making it an appropriate choice for elderly patients or those with pre-existing cognitive impairment 5, 6
Patients with Renal Impairment
Critical dosing adjustments based on creatinine clearance:
- Severe renal impairment (CrCl <30 mL/min): Extended-release formulation is NOT recommended 1
- Moderate renal impairment: Consider dose reduction for immediate-release formulation, as trospium is predominantly (70%) renally excreted as unchanged drug 2
- Rationale: Trospium has a renal clearance of 29 L/h accounting for approximately 70% of total clearance, and elimination is significantly slowed in renal insufficiency 2
Patients with Hepatic Impairment
No dose adjustment is typically required, as trospium undergoes minimal hepatic metabolism (only ~10% metabolized via spontaneous hydrolysis to spiroalcohol) 2, 6
Important Clinical Considerations
Drug Interaction Profile
Trospium has minimal drug-drug interactions because it:
- Does not bind to cytochrome P450 enzymes 5, 2
- Is excreted predominantly unchanged in urine
- Makes it an excellent choice for elderly patients on polypharmacy 6
Contraindications and Cautions
Per FDA labeling and guidelines 1:
- Absolute contraindications: Uncontrolled narrow-angle glaucoma, urinary retention, gastric retention, myasthenia gravis
- Use with extreme caution: Bladder outflow obstruction, gastrointestinal obstructive disorders, controlled narrow-angle glaucoma (only with ophthalmologist approval)
- Avoid alcohol within 2 hours of extended-release administration 1
Positioning in Treatment Algorithm
According to AUA/SUFU guidelines, trospium is recommended as second-line therapy after behavioral interventions 7:
- First-line: Behavioral therapies (bladder training, pelvic floor exercises, fluid management)
- Second-line: Oral antimuscarinics including trospium—no hierarchy implied among antimuscarinic agents 7
- Behavioral and antimuscarinic therapies may be combined 7
Common Pitfalls to Avoid
- Food interaction: Ensure patients understand to take on empty stomach (food reduces bioavailability to 26% of fasting levels) 2
- Renal function oversight: Always check creatinine clearance before prescribing, especially in elderly patients who may have normal serum creatinine despite reduced GFR 8
- Unrealistic expectations: Educate patients that complete symptom resolution is uncommon; most experience significant but not complete improvement 7
- Premature discontinuation: Continuation rates for antimuscarinics are low; proper counseling on expected benefits and side effects is essential 5